Anti-Human GPC3 Single Domain Antibody (TAB-416CQ), Research Grade Biosimilar (CAT#: TAB-416CQ)
This antibody binds to a unique conformational epitope in the native form of GPC3 core protein on cancer cells with high affinity. The binding requires both the N-terminus and C-terminus domains of GPC3, and is independent of the HS chains on GPC3.
Specific Inquiry
ELISA
Figure 1 Binding properties of HN3 antibody.
Protein-binding affinity was measured by ELISA using purified GPC3-hFc. (D) Measurement of cell-binding affinity by FACS using the G1 cell line.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
Figure 2 Binding properties of HN3 antibody.
Measurement of cell-binding affinity by FACS using the G1 cell line.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
IP
Figure 3 Binding properties of HN3 antibody.
Immunoprecipitation assay using coexpressed GPC3 N- and C-terminal fragments.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
IHC
Figure 4 Binding properties of HN3 antibody.
HCC tissue immunohistochemistry staining with HN3.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
FuncS
Figure 5 The effect of yap deregulation on HN3 function.
HN3 treatment of yap-knockdown cells. Proliferation was normalized with unengineered cells without antibody treatment.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
FuncS
Figure 6 The effect of yap deregulation on HN3 function.
HN3 treatment of cells overexpressing yap-S127A.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
WB
Figure 7 The effect of yap deregulation on HN3 function.
Western blot analysis of molecular changes after HN3 treatment on yap-knockdown cells or cells overexpressing yap-S127A.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
ELISA
Figure 8 Inhibition of HCC xenograft tumor growth by HN3 antibody.
Pharmacokinetics of HN3 antibody. Serum concentrations of the antibody were measured by ELISA following a single i.v. injection of 3 mg/kg. The serum antibody concentration data were fitted with a two-compartment model using Phoenix WinNonlin software. The observed mean serum antibody concentration (in micrograms per milliliter) ± SD of four animals for each time point was plotted as a function of time.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
Inhib
Figure 9 Inhibition of HCC xenograft tumor growth by HN3 antibody.
Inhibition of HepG2 cells inoculated into nude mice. After the tumor size reached 100 mm³, HN3 antibody or hIgG control was delivered i.v. at 60 mg/kg body weight, twice a week. Arrows indicate antibody injections.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
Inhib
Figure 10 Inhibition of HCC xenograft tumor growth by HN3 antibody.
Inhibition of Huh-7 cells inoculated into nude mice. After the tumor size reached 100 mm³, HN3 antibody or hIgG control was delivered i.v. at 60 mg/kg body weight, twice a week. Arrows indicate antibody injections.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
WB
Figure 11 Inhibition of HCC xenograft tumor growth by HN3 antibody.
Western blot analysis of molecular changes in HN3-treated and control tumors.
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.
Specifications
- Host Species
- Human
- Derivation
- Phage display library
- Type
- Single domain antibody
- Specificity
- Human
- Species Reactivity
- Human
- Clone
- TAB-416CQ
- Applications
- Immunoprecipitation, Immunohistochemistry, Functional Assay, Western Blot, ELISA, Inhibition
- Related Disease
- Hepatocellular carcinoma
Applications
- Application Notes
- The antibody was validated for Immunoprecipitation, Immunohistochemistry, Functional Assay, Western Blot, ELISA, Inhibition. For details, refer to Published Data.
Target
- Alternative Names
- GPC3; glypican 3; SGB; DGSX; MXR7; SDYS; SGBS; OCI-5; SGBS1; GTR2-2; glypican-3; secreted glypican-3; glypican proteoglycan 3; intestinal protein OCI-5; heparan sulphate proteoglycan
- Gene ID
- 2719
- UniProt ID
- P51654
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "GPC3"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single-domain Antibody
Humanized Antibody
Immunotoxin
Recombinant Antibody
Chimeric Antibody
Human Antibody
Mouse Antibody
MHC Tetramer for Cancer
Rabbit Monoclonal Antibody
Fab Fragment Antibody
scFv Fragment Antibody
ADCC Enhanced Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NABG-069 | Recombinant Anti-Mouse Gpc3 VHH Single Domain Antibody | WB, ELISA, IHC, FuncS | Llama VHH |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-416CQ. Click the button above to contact us or submit your feedback about this product.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-416CQ, RRID: AB_3111929)
Copy citation
Popular products with customers
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, FC, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: Inhib, ELISA, FC, FuncS
Application: EM, ELISA, ICC, IHC-Fr, IHC-P, WB
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
